title: [New anticoagulants: dabigatran, rivaroxaban and apixaban].
abstract: To date, the most widely used drugs in our anticoagulation clinics are acenocoumarin and warfarin, which belong to the category of vitamin K antagonists (VKA). They have about 70 years of use in the clinic, with proven efficacy for various thrombotic diseases, but also with known problems of variability and dietary and drug interactions. In hospital thromboprophylaxis, the most widely used anticoagulant is enoxaparin, a low molecular weight heparin (LMWH). A new generation of anticoagulants are available, the direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban and apixaban), with obvious advantages over conventional anticoagulants. This paper summarizes what has been published to date for these new antithrombotics.
authors: Departamento de Hematología y Oncología, Instituto Nacional de Nutrición Salvador Zubirán, México, D.F. gelocoa@hotmail.com
authors: Angel Gabriel
authors: AG
authors: Vargas Ruiz
authors: Alba Nydia
authors: AN
authors: Ramírez López
authors: Mónica Elizabeth
authors: ME
authors: Medina Viramontes
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D019637:Orthopedic Procedures / Q000009:adverse effects; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D054556:Venous Thromboembolism / Q000188:drug therapy; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran